Phase II study of biweekly docetaxel and S-1 combination chemotherapy as first-line treatment for advanced gastric cancer

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 6, 2011, Pages 1363-1368

  Kunisaki, Chikara ^a   Takahashi, Masazumi ^b   Makino, Hirochika ^a   Oshima, Takashi ^a   Fujii, Shoichi ^a   Takagawa, Ryo ^a   Kimura, Jun ^a   Kosaka, Takashi ^a   Ono, Hidetaka A ^a   Akiyama, Hirotoshi ^a   Kameda, Kunio ^c   Kito, Fumihiko ^b   Morita, Satoshi ^a   Endo, Itaru ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b AKITA UNIVERSITY   (Japan)

^c YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

Docetaxel; Gastric cancer; Phase II; S 1

Indexed keywords

DEXAMETHASONE; DOCETAXEL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CANCER RECURRENCE; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTRECTOMY; HUMAN; INOPERABLE CANCER; LEUKOPENIA; LIVER DYSFUNCTION; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SKIN TOXICITY; STOMACH CANCER; THROMBOCYTOPENIA; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; OXONIC ACID; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS; TEGAFUR;

EID: 79959589472     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1433-7     Document Type: Article

References (17)

1. JemarA,MurrayT,WardEetal(2005)Cancerstatistics,2005.CACancerJClin55: 10-30(Pubitemid40310185)
2. ShirasakaT,ShimamatoY,OhshimoHetal(1996)Developmentofanovelformofanoral5- fluorouracilderivative(S-1)directed- thepotentiationofthetumorselectivecytotoxicityof5- fluorouracilbytwobiochemicalmodulators.AnticancerDrugs7:548- 557(Pubitemid26276346)
3. Lee SJ, Cho SH, Yoon JY et al (2009) Phase II study of S-1 monotherapy in paclitaxel- and cisplatin-refractory gastric cancer. Cancer Chemother Pharmacol 65:159-166
4. Morita S, Nakata B, Tsuji A et al (2007) A phase I study of combination therapy of the oral fluorinated pyrimidine compound S-1 with low-dose cisplatin twice-a-week administration (JFMC27-9902 Step2) in patients with advanced gastric cancer using a continual reassessment method. Jpn J Clin Oncol 37:924-929 (Pubitemid 351176483)
5. Koizumi W, Akiya T, Sato A, Tokyo cooperative oncology group (TCOG GI Group) et al (2009) Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial. Jpn J Clin Oncol 39:713-719
6. Lorenzen S, Hentrich M, Haberl C et al (2007) Split-dose docetaxel, cisplatin and leucovorin/fluorouracil as first-line therapy in advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: results of a phase II trial. Ann Oncol 18:1673-1679 (Pubitemid 47506254)
7. Richards D, McCollum D, Wilfong L et al (2008) Phase II trial of docetaxel and oxaliplatin in patients with advanced gastric cancer and/or adenocarcinoma of the gastroesophageal junction. Ann Oncol 19:104-108
8. Ajani JA, Moiseyenko VM, Tjulandin S et al (2007) V-325 study group. Quality of life with docetaxel plus cisplatin and fluorouracil compared with cisplatin and fluorouracil from a phase III trial for advanced gastric or gastroesophageal adenocarcinoma: the V-325 study group. J Clin Oncol 25:3210-3216 (Pubitemid 47325603)
9. Takahashi I, Emi Y, Kakeji Y et al (2005) Increased antitumor activity in combined treatment TS-1 and docetaxel. Oncology 68:130-137
10. Takahashi I, Emi Y, Kakeji Y et al (2006) Phase I study of S-1 and biweekly docetaxel combination chemotherapy for advanced and recurrent gastric cancer. Oncology Rep 15:849-854
11. Rino Y, Takanashi Y, Yukawa N et al (2006) A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer. Anticancer Res 26:1455-1462
12. Kunisaki C, Takahasi M, Nagahori Y et al (2008) Phase I study of biweekly docetaxel and S-1 combination chemotherapy for advanced gastric cancer. Anticancer Res 28:2473-2478
13. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
14. Yoshida K, Ninomiya M, Takakura N et al (2006) Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 12:3402-3407
15. Yamaguchi K, Shimamura T, Hyodo I et al (2006) Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 94:1803-1808 (Pubitemid 43884569)
16. Wada Y, Yoshida K, Suzuki T et al (2006) Synergistic effects of docetaxel and S-1 by modulating the expression of metabolic enzymes of 5-fluorouracil in human gastric cancer cell lines. Int J Cancer 119:783-791 (Pubitemid 44055889)
17. Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215-221